Paragon 28 Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Paragon 28 ha un patrimonio netto totale di $139.4M e un debito totale di $110.6M, che porta il suo rapporto debito/patrimonio netto a 79.3%. Le sue attività totali e le sue passività totali sono rispettivamente $302.0M e $162.6M.

Informazioni chiave

79.3%

Rapporto debito/patrimonio netto

US$110.62m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$39.15m
Patrimonio netto	US$139.43m
Totale passività	US$162.58m
Totale attività	US$302.01m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $177.6M ) di 7GQ superano le sue passività a breve termine ( $50.7M ).

Passività a lungo termine: Le attività a breve termine di 7GQ ( $177.6M ) superano le sue passività a lungo termine ( $111.9M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 51.3% ) di 7GQ è considerato alto.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di 7GQ si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 7GQ ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: 7GQ ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 38.6 % ogni anno

Paragon 28 Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023)

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold €420k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021)

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new directors

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes

High number of new directors

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane